Eloisa Yuste

List of Publications by Year in descending order

34 papers	1,497 citations	393982 19 h-index	377514 34 g-index
34 all docs	34 docs citations	34 times ranked	2296 citing authors

#	Article	IF	Citations
1	Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses. Journal of Virology, 2022, 96, JVI0134321.	1.5	10
2	Evaluation of the Thermal Stability of a Vaccine Prototype Based on Virus-like Particle Formulated HIV-1 Envelope. Vaccines, 2022, 10, 484.	2.1	2
3	Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant. PLoS ONE, 2018, 13, e0208345.	1.1	8
4	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. PLoS ONE, 2018, 13, e0193773.	1.1	24
5	Structural Study of a New HIVâ€1 Entry Inhibitor and Interaction with the HIVâ€1 Fusion Peptide in Dodecylphosphocholine Micelles. Chemistry - A European Journal, 2017, 23, 11703-11713.	1.7	10
6	Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 601-609.	1.7	9
7	Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. Journal of Virology, 2016, 90, 5231-5245.	1.5	31
8	Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1139-1148.	1.1	18
9	Antibody-Based Preventive and Therapeutic Strategies Against HIV. Current HIV Research, 2016, 14, 260-269.	0.2	1
10	HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity. PLoS ONE, 2015, 10, e0134054.	1.1	5
11	Systematic Analysis of Intracellular Trafficking Motifs Located within the Cytoplasmic Domain of Simian Immunodeficiency Virus Glycoprotein gp41. PLoS ONE, 2014, 9, e114753.	1.1	6
12	Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs. Beilstein Journal of Organic Chemistry, 2014, 10, 1339-1346.	1.3	69
13	Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. Journal of Translational Medicine, 2013, 11, 48.	1.8	3
14	Evolution of Broadly Cross-Reactive HIV-1-Neutralizing Activity: Therapy-Associated Decline, Positive Association with Detectable Viremia, and Partial Restoration of B-Cell Subpopulations. Journal of Virology, 2013, 87, 12227-12236.	1.5	18
15	HIV-1 Inhibiting Capacity of Novel Forms of Presentation of GB Virus C Peptide Domains is Enhanced by Coordination to Gold Compounds. Current Medicinal Chemistry, 2013, 21, 238-250.	1.2	8
16	Evidence against Extracellular Exposure of a Highly Immunogenic Region in the C-Terminal Domain of the Simian Immunodeficiency Virus gp41 Transmembrane Protein. Journal of Virology, 2012, 86, 1145-1157.	1.5	19
17	Low-Replicating Viruses and Strong Anti-Viral Immune Response Associated with Prolonged Disease Control in a Superinfected HIV-1 LTNP Elite Controller. PLoS ONE, 2012, 7, e31928.	1.1	21
18	Gold Nanoparticles Coated with Oligomannosides of HIV-1 Glycoprotein gp120 Mimic the Carbohydrate Epitope of Antibody 2G12. Journal of Molecular Biology, 2011, 410, 798-810.	2.0	72

#	Article	IF	Citations
19	A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine, 2011, 29, 5250-5259.	1.7	38
20	Broadly Cross-Neutralizing Antibodies in HIV-1 Patients with Undetectable Viremia. Journal of Virology, 2011, 85, 5804-5813.	1.5	37
21	Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIVmac239. PLoS Pathogens, 2009, 5, e1000272.	2.1	32
22	Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nature Medicine, 2009, 15, 901-906.	15.2	279
23	Glycosylation of gp41 of Simian Immunodeficiency Virus Shields Epitopes That Can Be Targets for Neutralizing Antibodies. Journal of Virology, 2008, 82, 12472-12486.	1.5	22
24	Potent Antibody-Mediated Neutralization and Evolution of Antigenic Escape Variants of Simian Immunodeficiency Virus Strain SIVmac239 In Vivo. Journal of Virology, 2008, 82, 9739-9752.	1.5	23
25	A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology, 2007, 360, 329-340.	1.1	94
26	Simian Immunodeficiency Virus Engrafted with Human Immunodeficiency Virus Type 1 (HIV-1)-Specific Epitopes: Replication, Neutralization, and Survey of HIV-1-Positive Plasma. Journal of Virology, 2006, 80, 3030-3041.	1.5	72
27	Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5Â. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19134-19139.	3.3	149
28	Few Mutations in the 5â€² Leader Region Mediate Fitness Recovery of Debilitated Human Immunodeficiency Type 1 Viruses. Journal of Virology, 2005, 79, 5421-5427.	1.5	18
29	Virion Envelope Content, Infectivity, and Neutralization Sensitivity of Simian Immunodeficiency Virus. Journal of Virology, 2005, 79, 12455-12463.	1.5	49
30	Modulation of Env Content in Virions of Simian Immunodeficiency Virus: Correlation with Cell Surface Expression and Virion Infectivity. Journal of Virology, 2004, 78, 6775-6785.	1.5	80
31	Frequency-dependent selection in human immunodeficiency virus type 1. Journal of General Virology, 2002, 83, 103-106.	1.3	17
32	In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. Journal of General Virology, 2002, 83, 93-101.	1.3	44
33	Unusual Distribution of Mutations Associated with Serial Bottleneck Passages of Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 9546-9552.	1.5	49
34	Drastic Fitness Loss in Human Immunodeficiency Virus Type 1 upon Serial Bottleneck Events. Journal of Virology, 1999, 73, 2745-2751.	1.5	160